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Abstract. 
 
Background. Anti-staphylococcal penicillins (ASPs) are recommended as first-line agents in 
methicillin-susceptible Staphylococcus aureus (MSSA) bacteremia. Concerns about the safety 
profile have contributed to the increased use of cefazolin. The comparative clinical 
effectiveness and safety profile of cefazolin versus ASPs for such infections remain unclear. 
Furthermore, uncertainty persists concerning the use of cefazolin due to controversies over its 
efficacy in deep MSSA infections and its possible negative ecological impact.  
Aims. The aim of this narrative review was to gather and balance available data on the 
efficacy and safety of cefazolin versus ASPs in the treatment of MSSA bacteremia and to 
discuss the potential negative ecological impact of cefazolin.  
Sources. PubMed and EMBASE electronic databases were searched up to May 2017 in order 
to retrieve available studies on the topic. 
Contents. While described in vitro and in experimental studies, the clinical relevance of the 
inoculum effect during cefazolin treatment of deep MSSA infections remains unclear. It 
appears that there is no significant difference in rate of relapse or mortality between ASPs and 
cefazolin for the treatment of MSSA bacteremia but these results should be cautiously 
interpreted because of the several limitations of the available studies. Compared to cefazolin, 
there is more frequent discontinuation for adverse effects with ASPs use, especially because 
of cutaneous and renal events. No study has evidenced any change in the gut microbiota after 
the use of cefazolin.  
Implications. Based on currently available studies, there is no data allowing to choose one 
antibiotic over the other except in patients with allergy or renal impairment. This review 
points out the need for future prospective studies and randomized controlled trials to better 
address these questions. 
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1. Background 
Methicillin-susceptible Staphylococcus aureus (S. aureus) (MSSA) bacteremia remains a 
major cause of community- or hospital-acquired bloodstream infections, with approximately 
200,000 cases occurring annually in Europe [1] and high in-hospital mortality (25-35%) [2–
4]. Anti-staphylococcal penicillins (ASPs) such as oxacillin or cloxacillin are recommended 
as first-line agents, but their use may be limited by concerns about their safety profile and 
difficult dosing schedule in patients with renal failure. Cefazolin, an intravenous first-
generation cephalosporin, (1GC) is thus more and more used as an alternative option [5,6]. 
Yet the comparative clinical effectiveness and safety profile of cefazolin versus ASPs 
(nafcillin, oxacillin, cloxacillin, dicloxacillin or flucloxacillin) for MSSA infections remain 
unclear because of the limited published data. Furthermore, uncertainty persists for the 
curative use of cefazolin because of controversies concerning its efficacy in high-inoculum 
deep MSSA infections and its possible negative ecological impact.  
 
2. Aims 
The aim of this narrative review was to gather and balance available data on the efficacy and 
safety of cefazolin versus ASPs in the treatment of MSSA bacteremia and to discuss the 
potential negative ecological impact of cefazolin.  
 
3. Sources  
An extensive search of PubMed (January, 1985, to May, 2017) and EMBASE (January, 2010, 
to May, 2017) was performed to identify relevant studies for our review. Search terms 
included “cefazolin”, “oxacillin”, “nafcillin”, “antistaphyloccocal penicillin”, “methicillin”, 
“β-lactams”, “bacteremia”, “bacteraemia”, “bloodstream infection”, “efficacy”, “safety”, 
“effectiveness”, “inoculum effect”, “gut microbiota”, “resistances”, “Staphylococcus aureus”, 
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and “MSSA”. The reference lists of all articles retrieved were checked for additional relevant 
references. Two reviewers (PL and FXL) independently searched the literature and examined 
relevant studies. A study was considered eligible if the role of cefazolin in comparison with 
an anti-staphylococcal penicillins in the treatment of infections caused by methicillin-
susceptible Staphylococcus aureus was assessed. Furthermore, clinical or experimental 
studies dealing with the existence of an inoculum effect with the use of cefazolin and 
occurrence of changes in gut microbiota following cefazolin and ASP use were included. 
Only studies published in English were considered in this review.  
 
4. Content 
a. Inoculum effect  
The inoculum effect has been defined as a significant rise in the cefazolin minimum inhibitory 
concentration (MIC) when the bacterial inoculum size is increased to 10
7
 colony-forming 
units (CFU)/mL (instead of the standard 10
5
 CFU/mL) [7]. Four different types (A, B, C and 
D) of staphylococcal β-lactamase enzymes have been characterized based on their substrate 
specificity and amino acid sequence [8], and each of these has a different substrate profile [9]. 
An inoculum effect of β-lactamase in MSSA has been suggested in vitro, with an MIC 
increase especially with blaZ type A β-lactamase. Type A β-lactamase efficiently hydrolyzes 
cefazolin [10], but, not all isolates producing type A β-lactamase exhibit a significant 
cefazolin inoculum effect [11–14] because of mechanisms that are not clearly known [15]. 
However, a recent study has suggested that there might exist an association between type A 
blaZ gene polymorphism and cefazolin inoculum effect [16].  
In our review, the prevalence of β-lactamase ranges from 77 to 92% while Type A 
represents 15-34% and a cefazolin inoculum effect was found in 13 to 58% of the MSSA 
isolates. It seems that no significant association exists between inoculum effect positivity 
5 
 
and demographic factors, underlying disease or site of infection [17] even though one study 
found that osteomyelitis is highly associated with cefazolin inoculum effect in South 
American hospitals [14]. Five studies assessed the clinical outcomes of the patients from 
whom MSSA isolates were collected depending on the presence of an inoculum effect. None 
found an impact of inoculum effect on mortality at day 90 and/or treatment failure. However, 
none of the studies was powered enough to evaluate the clinical impact of the cefazolin 
inoculum effect and the blaZ gene type. (Table 1) 
In vivo results are conflicting (Table 2). Studies of MSSA infective endocarditis have shown 
that the in vitro inoculum effect may have consequences [18–20], whereas other studies 
suggest that the slow inactivation of cefazolin by staphylococcal β-lactamase is of little 
importance, because diffusion into the area of infection occurs rapidly enough to yield 
effective antibacterial concentrations [21].  
In conclusion, the hydrolysis of cefazolin by S. aureus type A -lactamases in high-inoculum 
deep infections has been proven in vitro. However, its frequency in MSSA bacteremia has 
been found to be limited, ranging from 13 to 58% [12–14,17,22,23]. The fact that it may lead 
to potential therapeutic failures is still debated with conflicting results in animal studies and 
six human studies that found no impact of the inoculum effect. However, these studies are 
limited by their small sample size, low rate of deep-seated infections and the presence of 
selection bias. Furthermore, the fact that neither susceptibility testing for cefazolin for MSSA 
nor the presence of type A -lactamases are routinely tested makes it difficult to gather data 
on the topic and to establish practical recommendations.  
b. Clinical efficacy (Table 3) 
Cloxacillin and cefazolin are more effective in the treatment of MSSA bacteremia than 
alternative treatments, with 2-fold and 3-fold increases in mortality rate with other β-lactams 
[24] and vancomycin [25–29], respectively.  
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Although ASPs are the recommended treatment in MSSA bacteremia, the use of cefazolin in 
increasing. However, the quantity and quality of publishing data comparing clinical 
effectiveness of cefazolin versus ASPs are limited. So far, seven observational studies have 
compared cefazolin to ASPs in the treatment of MSSA bacteremia [24,30–35]. Six of these 
studies found no difference in treatment failure and/or mortality between cefazolin and ASPs 
groups with half of the studies reporting that cefazolin was associated with non-significant 
lower mortality [32–34]. The more recent study from McDanel et al., which is the largest one 
with 1163 patients in the cefazolin group and 2004 patients in the ASPs group found that 
cefazolin was significantly associated with lower mortality (aHR 0.8 [0.7-0.9]). 
Details on patients and infections characteristics, antibiotics dosing and duration, outcomes of 
interest and methods to control bias in the seven studies are displayed in Table 1.  
All of these studies have several limitations. First, they all are retrospective with small sample 
size (except for McDanel et al.). Second, important data such as, type and duration of empiric 
therapy before the start of cefazolin or ASPs, duration of bacteremia, antibiotics dosing, rates 
of metastatic infection and source control, are often missing. Third, the rate of deep seated 
infections, defined as endocarditis, bone or joint infection, device related infection, deep-
seated abscess and pneumonia is relatively small. Fourth, while ASP dosing was the same 
across the studies, cefazolin dosing ranged from 3g/day to 6g/day making comparison 
difficult between studies. Finally, despite statistical adjustments to allow better comparison 
between groups, these studies are facing selection biases with imbalances between study 
groups with more severe, including more deep-seated and metastatic, infections and less 
source control in the ASP groups. Results of studies showing a better efficacy of cefazolin 
may be partly explained by the fact that cefazolin was used in less severe patients mostly with 
catheter or skin and soft tissue related bacteremia with easier source control and thus should 
be cautiously interpreted.  
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c. Safety (Table 4) 
Patients with MSSA infection often require prolonged administration of high-dose parenteral 
antimicrobial therapy with standard doses of 12 grams per day for oxacillin (25 to 50 mg/kg/4 
to 6 hours) and 6 grams per day for cefazolin (25 to 50 mg/kg/8h). Because of aging and 
cumulating comorbidities in these patients, safety issues following the use of ASPs are not 
infrequent, especially hypersensitivity reactions (more than 10%) [36,37] and renal 
impairment (more than 10%) [38]. Premature discontinuation of ASPs attributed to adverse 
events have been reported in 17 to 21% of treated patients for complicated MSSA bacteremia 
with standard doses of oxacillin or nafcillin (12g/24h) [30,31]. In the case of chronic kidney 
disease with decreased glomerular filtration rate, ASP dosing is not clearly known. 
Five studies have compared the occurrence of adverse events between cefazolin and ASPs 
among patients treated for MSSA bacteremia [30,31,33,38,39]. All but one study report 
higher adverse drug events in ASPs groups mainly due to nephrotoxicity and hypersensitivity 
reactions. These adverse drug events often required antibiotics discontinuation.  
It appears that adverse event and criteria for discontinuation are not clearly defined across the 
studies with a wide range of nephrotoxicity definition for example. Furthermore, due to the 
retrospective nature of these studies, the quality of data collection is poor with important 
information biases. As for all observational studies, selection biases affect these safety 
studies. Severe patients, more likely to be concerned by acute renal failure or overdosing, are 
more frequently treated with ASPs.  
d. Ecological impact on gut microbiota 
In the current context of growing bacterial resistance, especially 3GC-resistant 
Enterobacteriaceae, the potential negative gut ecological impact of cephalosporins compared 
to very narrow spectrum antibiotics such as ASPs is largely debated. From a theoretical point 
of view, high biliary excretion of antibiotics and a sparing spectrum for anaerobes and 
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lactobacilli may foster selection of high MIC Enterobacteriaceae, Clostridia and Candida by 
influencing the ecological balance of the gut microbiota. The biliary excretion of cefazolin is 
low and amounted to 0.03% of the administered dose, while 2–10% of a dose of cloxacillin or 
oxacillin can be recovered from bile [40]. 
i. Ecological effect of ASPs on gut microbiota 
 
Although, there are many studies of the effects of ASPs on skin flora, data on the ecological 
effects of ASPs on gut microbiota are scarce. Narrow spectrum penicillins seem to present a 
low risk for diarrhea associated with C. difficile in a systematic literature review published in 
1998; ASPs seemed to present one of the lowest risks (OR 3.2; 95% CI 1.7–6.2), close to that 
of vancomycin (3.1; 95% CI 1.8–5.2), and much lower than broad spectrum antibiotics such 
as amoxicillin/clavulanic acid combination for example (22.1; 95% CI 6.5–75.4) [41].  
A Japanese study assessed the effect of antibiotics on the fecal flora in hospitalized children 
aged from 1 to 12 years, who received ampicillin (n=6), methicillin (n=8), cefpiramide (n=7) 
or ceftazidime (n=7). Antibiotic use was given for 5 to 14 days. Fifteen same aged 
hospitalized children who did not receive any antimicrobials served as controls. There was no 
significant decrease in the count of Enterobacteriaceae in patients treated with methicillin 
[42]. 
ii. Ecological effect of C1G on gut microbiota 
Ambrose et al. studied the influence of a single intravenous dose of antibiotic on gut 
microbiota and the emergence of C. difficile over two weeks in 78 volunteers (13 groups of 6 
volunteers). Each group of 6 received either penicillins, from among benzyl penicillin, 
ampicillin, mezlocillin, piperacillin, ticarcillin, or cephalosporins, from among 1CG to 3CG, 
and the results were compared with those for a control group of 6 volunteers who received no 
antibiotic. Only cephalosporins were found to be associated with emergence of C. difficile, 
penicillins and controls were not. When they considered total aerobic counts, only the 
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reduction after ceftriaxone achieved statistical significance (P<0.025) with decrease in counts 
of Escherichia coli, though an increase in the counts of enterococci was also observed in all 
groups. For the anaerobe count, only cefotetan was associated with a trend for decrease. 
Overall, no significant changes were observed for cefazolin [43]. 
Knothe et al. investigated in healthy volunteers the effects on gut microbiota of 1GC 
(cefazolin) and 3CG (cefotaxime). One or two stool specimens were taken before, during and 
several days after medication. No selection of strains resistant to ampicillin or cefazolin 
occurred, while cefazolin considerably reduced Bacteroides spp., lactobacilli and 
Enterobacteriaceae [44].  
Finally, Takesue et al. investigated changes in gut microbiota in 24 patients given intravenous 
antibiotics for a 4-day period after gastrectomy. Patients were divided into 3 groups with 1CG 
(cefazolin), 2CG (flomoxef) and 4GC (cefozopran). Cefazolin had less of an effect on the gut 
microbiota changes. Flomoxef caused the most remarkable change in anaerobic bacteria while 
the number of Enterobacteriaceae decreased significantly only with 4CG. [45].  
While, the negative ecological impact of cephalosporin use is known, few clinical studies 
specifically assessed the impact of 1GC on gut microbiota [43–45]. Indeed, despite its wide 
use in antimicrobial prophylaxis in surgical care, no study has clearly assessed the ecological 
impact of cefazolin. In the reviewed studies, no change in counts of Enterobacteriaceae, 
enterococci, yeasts, total anaerobes, Clostridia spp. or Bacteroides spp. was observed after 
administration of cefaloridine, cefalotine or cefazolin. However, it seems that significant 
changes begin from second cephalosporin generations use [43]. 
In the current era of growing antimicrobial resistance, the ecological impact has to be 
considered among potential adverse effects of antibiotics, especially when one has to balance 
between penicillin and cephalosporin. The more appropriate populations to assess gut 
microbiota dysbiosis under antimicrobial are healthy volunteers as well as patients undergoing 
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surgery and receiving antimicrobial prophylaxis. Unfortunately, too few studies have been 
done in these populations. Furthermore, judgement criteria used in available studies are not 
accurate enough to conclude. Finally, it has to be underlined that none of the studies assessed 
emergence of 3GC resistant Enterobacteriaceae and that genetic sequencing methods have 
not been used to analyze stools. Waiting for such data, cefazolin appears to have a very 
limited gut ecological impact. 
 
5. Implications 
The quality of the published data comparing ASPs and cefazolin as treatment options for 
MSSA bacteremia is insufficient while the associated morbidity and mortality are high in this 
frequent disease. While described in vitro and in experimental studies, the clinical relevance 
of the inoculum effect during cefazolin treatment of deep MSSA infections remains uncertain. 
This inoculum effect which appears to be infrequent, is not routinely tested in microbiological 
labs making its impact difficult to assess in routine care.  
From a clinical point of view, it seems that there is no difference in efficacy between these 
drugs. However, available data on clinical efficacy are from retrospective studies that are 
affected by selection biases issue. Despite concerns about the possible negative ecological 
impact of cefazolin, no studies have evidenced changes in gut microbiota after its use, but the 
designs of the available studies are all too old to be able to correctly assess this issue. 
Concerning safety, it appears that adverse events, especially cutaneous and renal, are more 
frequent with ASPs than with cefazolin. All these points need to be confirmed in randomized 
controlled trials that should take into account ecological data.  
Based on these reviewed data and our clinical experience, we suggest using cefazolin in 
catheter related infections, skin/soft tissue infection, non-complicated IE and bone and joint 
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infection because of the excellent bone penetration [46,47]. Conversely, because of the poor 
penetration of cefazolin through the blood-brain barrier [48,49], ASPs should be preferred for 
central nervous system infections. In case of complicated IE and deep-seated abscesses, 
because of the hypothetical risk of clinical failure due to the inoculum effect, ASPs should 
rather be considered along with source control when possible. In case of deep-seated infection 
and complete stock-out of ASPs, source control and an increase in cefazolin dosing (>6g/day) 
should help mitigating the inoculum effect.  
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Table 1. Characteristics and results of studies assessing in vitro and in vivo inoculum effect in humans 
 
 
Study 
Design 
Number of 
MSSA 
bacteremia 
Infection sites 
Prevalence 
of BlaZ 
(%)* 
Type 
Definition 
of IE 
Prevalence 
of IE (%) 
Comment 
Clinical 
Outcomes¶ 
Number of 
patient 
with IE  
 
Number of 
patient 
without IE  
 
Results 
Nannini 
et al. 
2009 
 
Multicenter 
Retrospective 
study 
98 
Endocarditis 30% 
Hospital acquired 
Pneumonia 30% 
Skin and soft tissue 
29% 
Unknown 11% 
87 
Type A 
26% 
Type B 
15% 
Type C 
46% 
MIC >16 
µg/mL 
with 107 
CFU/mL 
19 
At high inoculum, type A 
producers displayed higher 
cefazolin MICs than type B 
or C producers (11.2 vs. 2.8 
(p=0.002) and 5.6 µg/mL 
(p=0.04) respectively) 
Treatment 
failure 
3 9 
3 (100%) vs 3 
(33%) p=0.2 
Livorsi 
et al. 
2012 
Multicenter 
Retrospective 
study 
185 
Unknown 46% 
Bone and joint 16% 
Catheter related 
14% 
Endocarditis 9% 
Pneumonia 7% 
77 
Type A 
34% 
Type B 
30% 
Type C 
35% 
Type D 
1% 
≥4-fold 
increase in 
MIC from 
a standard 
to a high 
inoculum 
27 
4% of isolates (8/185), all 
type A Bla strains, 
demonstrated a non-
susceptible cefazolin MIC. 
D90 
Treatment 
failure 
2 5 
No significant 
differences 
between the 
two groups 
Rincon 
et al 
2013 
Multicenter 
Retrospective 
study 
296 NA NA 
Type A 
67% 
Type C 
29% 
MIC >16 
µg/mL 
with 107 
CFU/mL 
33 - NA NA NA - 
Chong 
et al. 
2014 
Single center 
Retrospective 
study 
220 NA 92 
Type A 
17% 
Type B 
20% 
Type C 
53% 
≥4-fold 
increase in 
MIC from 
a standard 
to a high 
inoculum 
13 - 
Relapse of 
infection 
D90 Mortality 
Treatment 
failure 
10 67 
0 (0%) vs 
2(4%) p=1 
2 (20%) vs 12 
(18%) p=1 
0 (0%) vs 10 
(15%) p=0.34 
Lee 
et al. 
2014 
Multicenter 
Retrospective 
study 
113 
Skin and soft tissue 
35% 
Unknown 20% 
Catheter related 
18% 
78 
Type A 
15% 
Type C 
41% 
≥4-fold 
increase in 
MIC from 
a standard 
to a high 
inoculum 
58 - 
Treatment 
failure 
65 48 
IE was not 
associated 
with treatment 
failure 
(aOR 1.3 
95%CI 0.4-
4.9, p=0.7) 
Song 
et al. 
2014 
Multicenter 
Retrospective 
study 
303 
Bone and joint 25% 
Skin and soft tissue 
22% 
Unknown 21% 
Pneumonia 14% 
Catheter related 
10% 
84 
Type A 
13% 
Type B 
27% 
Type C 
44% 
Type D 
0.3% 
MIC >16 
µg/mL 
with 107 
CFU/mL 
20 
CIE positivity was found to 
be significantly associated 
with the type of the blaZ 
gene. (56% (23/41) in Type 
A; 28% (37/132) in Type C 
and 1.2% (1/81) in Type B) 
D90 Mortality 61 242 
IE was not 
associated 
with treatment 
failure 
(OR 1.7 
95%CI 0.9-
3.3, p=0.13)£ 
MSSA: MSSA= Methicillin-Susceptible Staphylococcus,  IE: Inoculum Effect  
 *Percentage of strains producing Beta lactamase (Bla) 
¶ In patients with strains producing Bla and receiving cefazolin as a definitive therapy. 
£Univariate analysis 
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Table 2. Characteristics and results of studies assessing in vitro and vivo inoculum effect in animals 
 Model Antibiotics compared 
In vitro  In vivo 
Outcomes Results Outcomes Results 
Carrizosa et al. 
1979 
Experimental 
endocarditis in rabbits. 
Highly penicillin-
resistant strain of S. 
aureus. 
Cefazolin 
Cephalotin 
Methicillin 
Mean log10 CFU  (standard 
deviation) per gram of vegetation 
after 3 days of therapy 
 
Cefazolin every 6 hours: 4.2 ± 2.7 
Cefazolin every 8 hours: 4.7 ± 2.8 
Cephalothin: 4.5 ± 2.7 
 Methicillin: 2.0 ± 0 
(P < 0.01 for comparisons 
between methicillin and each of 
the three other groups). 
Positivity of 
 Blood cultures* 
Methicillin 0/10 (0%) 
Cefazolin (every 6 hours) 
2/13 (15%) 
Cefazolin (every 8 hours) 
2/13 (15%) 
Cephalothin: 3/13 (23%) 
Goldman and 
Petersdorf 
1980 
Experimental 
endocarditis in rabbits. 
Beta-lactamase-
positive 
vs. 
Beta lactamase 
negative strains 
Cefzaolin 
Cephalothin (1GC) 
Cefoxitin (2GC) 
Cephaloridin (1GC) 
Minimum Inhibitory 
Concentration 
(MIC) 
In β-lactamase-
producing strain   
The MIC of  cefazolin was 
increased with S. aureus 
inoculum, unlike other 
cephalosporins 
In  β-lactamase-negative strain,  
 MICs were stable for all 
antibiotics 
Day 4 mortality 
Cefazolin vs 
Cephalotin 
65% (13/20) vs 20% (4/20) 
(p<0.005) 
Kaye et al.  
1979 
Artificial 
intraperitoneal 
infection in rabbits 
Highly penicillin-
resistant strain. 
Cefazolin 
Cephalothin (1GC) 
Cefoxitin (2GC) 
Cefamandole (1GC) 
S. aureus bacterial counts in 
intraperitoneal infection after 8 
days of treatment 
(CFU/mL) 
Cefazolin: 1.6 log10,  
Cephalotin: 1.0 log10 
Cephoxitin: 1.9 log10 
Cefamandole: 3.6 log10  
- NA 
Nannini et al. 
2013 
Experimental 
endocarditis in rats. 
Type A β-lactamase 
producer strains 
(TX0117) vs. standard 
strains (TX0117c) 
Cefazolin 
Nafcillin  
Daptomycin 
 
With TX0117 strains 
CFU/g of vegetations  
(mean log10 +/- SD) after 3 days 
of treatment 
 
 
With TX0117c strains 
mean log10 reduction after 3 days 
of treatment 
With TX0117 strains 
Cefazolin: 5.5 +/- 2.0,  
Dpatomycine 0.2 +/- 0.4, 
Nafcillin 2.0 +/- 2.9  
(cefazolin versus daptomycin, p< 
0.0001;  
cefazolin versus nafcillin, p< 
0.005; daptomycin versus 
nafcillin, p = 0.053).  
 
With TX0117c strains 
Nafcillin 1.4 log10 Cefazolin 5.5 
(p=0.0001), 
- NA 
1GC: 1st Generation Cephalosporin; 2GC: 2nd Generation Cephalosporin 
*At the time of sacrifice, right atrial blood cultures 
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 Table 3. Characteristics and results of studies comparing efficacy of cefazolin versus anti-staphylococcal penicillins in the treatment of MSSA bacteremia. 
 
Study  
Design 
Mechanisms  
to control bias 
Antibiotics 
(dosing) 
Number of 
patients 
Severity of illness 
Deep seated infections¶ 
 
 
Duration of 
bacteremia in 
days 
(mean (SD) or 
median [IQR]) 
Metastatic 
infection 
Source 
control§ 
Paul et al. 2011 
1988 – 1994 & 
1999-2007 
Petah Tikva, Israel 
Single center 
Retrospective cohort 
Multivariate 
Logistic 
regression 
CFZ N = 72 
NA 19% NA NA NA 
Cloxacillin 
 
N = 281 
 
Lee et al. 2011 
2004 – 2009 
Seoul, South Korea 
Single center 
Retrospective cohort  
Propensity score 
CFZ 
N = 49 
N’ = 41 
Classified as ultimately or 
rapidly fatal according to 
McCabe score (%): 66 
32%* 
NA 
17% 29% 
Nafcillin 
 
N = 84 
N’ = 41 
Classified as ultimately or 
rapidly fatal according to 
McCabe score (%): 73 
55%* 15% 27% 
Li et al. 2014 
2008 – 2012 
San Antonio, Tx, USA 
Multicenter 
Retrospective cohort 
Multivariate 
Logistic 
regression 
CFZ 
(6g/day) 
N = 59 
ICU admission (%): 7 
Pitt Bacteremia Score 
(median, IQR): 0 [0-1] 
59% 4 [2-6] 34% 56% 
Oxacillin 
(12g/day) 
N = 34 
ICU admission (%): 18 
Pitt Bacteremia Score 
(median, IQR): 0 [0-1] 
76% 4 [3-7] 35% 50% 
Bai et al. 2015 
2007 – 2010 
Toronto, Canada 
Multicenter 
Retrospective cohort 
Propensity score 
CFZ 
(3g/day)  
N = 105 
N’ = 90 
ICU admission (%): 10 32% 
NA NA 
63% 
Cloxacillin 
(12g/day) 
N = 249 
N’ = 90 
ICU admission (%): 18 41% 58% 
Rao et al. 2015 
2010 – 2013 
Chicago, Il, USA 
Multicenter 
Retrospective cohort 
Multivariate 
Logistic 
regression 
CFZ 
(4g/day) 
N = 103 
ICU admission (%): 42 
Modified-APACHE score 
(mean, SD): 13 (6.3) 
31% 3 [2-4] 29%* 77%* 
Oxacillin 
(12g/day) 
N = 58 
ICU admission (%): 33 
Modified-APACHE score 
(mean, SD): 10.3 (5.8) 
35% 3 [2-4] 19% 52%* 
Pollet et al. 2016 
2008 – 2013 
San Francisco, Ca, 
USA 
Single center 
Retrospective cohort 
Propensity score 
CFZ N = 70 ICU admission (%): 13 14% 1.3 (0.8) 
NA NA 
Nafcillin N = 30 ICU admission (%): 27 30% 1.7 (1.4) 
McDanel et al. 2017 
2003 – 2010 
USA 
Multicenter 
Retrospective cohort 
- 
CFZ N = 1163 
ICU admission (%): 15 * 
APACHE III Score >34 (%): 
56 
41% NA 
NA NA 
Nafcillin/Oxac
illin 
N = 2004 
ICU admission (%): 19 * 
APACHE III Score >34 (%): 
52 
43%  
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Table 3 (continued). 
 
 Antibiotics 
(dosing) 
Number 
of 
patients 
Efficacy Outcomes Results Results 
Paul et al. 2011 
1988 – 1994 & 
1999-2007 
Petah Tikva, Israel 
CFZ N = 72 
Day 90 mortality 
40% 
Cefazolin aOR mortality  
0.91 [0.47–1.77] Cloxacillin 
 
N = 281 
 
32% 
Lee et al. 2011 
2004 – 2009 
Seoul, South Korea 
CFZ N’ = 41 
D90 Treatment failure 
(Change in antibiotic 
regimen, clinical failure, 
relapse or death) 
15% Cefazolin aOR treatment failure 
1.6 [0.5 – 5.4] 
Nafcillin N’ = 41 15% 
Li et al. 2014 
2008 – 2012 
San Antonio, Tx, USA 
CFZ N = 59 D90 Treatment failure 
(persistent bacteremia, 
progression of infection, 
relapse or death) 
47% 
- 
Oxacilline N = 34 24% 
Bai et al. 2015 
2007 – 2010 
Toronto, Canada 
CFZ N’ = 90 
Day 90 mortality 
Day 90 relapse 
20% vs 30% 
6% vs 2% 
Cefazolin HR mortality  
0.58 [0.31 – 1.08] Cloxacillin N’ = 90 
Rao et al. 2015 
2010 – 2013 
Chicago, Il, USA 
CFZ N = 103 
In-hospital mortality 
Treatment failure 
1% vs 5% 
6% vs 12% 
 
Oxacillin aOR treatment failure 
3.76 [0.98 – 14.4] Oxacillin N = 58 
Pollet et al. 2016 
2008 – 2013 
San Francisco, Ca, USA 
CFZ N = 70 
Day 90 mortality 
7%  
Cefazolin aOR mortality  
0.40 [0.09 – 1.74] Nafcillin N = 30 17% 
McDanel et al. 2017 
2003-2010 
USA 
CFZ N = 1163 
Day 90 mortality 
Day 90 recurrence 
25% vs 20%* Cefazolin aHR mortality  
0.77 [0.66 – 0.90] 
Cefazolin aHR recurrence  
1.13 [0.94 – 1.36] 
Nafcillin/Oxacillin N = 2004 20% vs 28% 
*p<0.05; aOR= adjusted odds ratio, CFZ=Cefazolin, HR= Hazard Ratio, MSSA= Methicillin-Susceptible Staphylococcus aureus, N’=number of included patients in the propensity score matched analyses,  
¶ Deep-seated infections: Endocarditis, Bone or joint infection, Device related infection, Deep-seated abcess, Pneumonia 
§Source control: Catheter removal, device explantation, surgical management of abcess 
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Table 4. Characteristics and results of studies assessing safety of cefazolin versus anti-staphylococcal penicillins use in the treatment of MSSA bacteremia. 
 
 Study Design Antibiotics 
(dosing) 
Dosing Median duration Number of patients Criteria Results 
Lee 2011 
2004 – 2009 
Seoul, South Korea 
Single center 
Retrospective cohort 
CFZ NA 17 [10-18] 
N = 49 
N’ = 41 
Discontinuation AE 
0%* 
Nafcillin NA 15 [10-25] 
N = 84 
N’ = 41 
17%* 
Youngster 2014 
2007 – 2011 
Boston, Ma, USA 
Retrospective cohort 
CFZ 6g/day NA N = 119 
Premature ATB discontinuation 
Rash 
Nephrotoxicity 
Hepatotoxicity 
7% vs 34% 
4% vs 14%* 
3% vs 11%* 
2% vs 8%* 
Nafcillin 8g/day NA N = 366 
Li 2014 
2008 – 2012 
San Antonio, Tx, USA 
Multicenter 
Retrospective cohort 
CFZ 6g/day 39 [28-44] N = 59 All AE 
Rash 
Elevated transaminases 
Elevated serum creatinine 
3% vs 30% * 
2% vs 3% 
0% vs 18%* 
0 vs 3% 
Oxacillin 12g/day 31 [21-42] N = 34 
Rao 2015 
2010 – 2013 
Chicago, Il, USA 
Multicenter 
Retrospective cohort 
CFZ 4g/day 29 [15-42] N = 103 Any AE 
Rash 
Nephrotoxicity 
Hepatotoxicity 
4% vs 8% 
0% vs 3% 
0% vs 1% 
0% vs 2% 
Oxacillin 12g/day 32.5 [15-43] N = 58 
Flynt 2017 
2010 – 2013 
Dertoit, MI, USA 
Multicenter 
Retrospective cohort 
CFZ NA NA N = 68 
Acute Kidney Injury 
13%* 
Naficillin NA NA N = 81 32%* 
 
*p<0.05 
AE= adverse event, ASPs= anti-staphylococcal penicillins, ATB= Antibiotics, CFZ= Cefazolin, MSSA= methicillin-susceptible Staphylococcus aureus, NA= not available. 
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